We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Highlights Its Innovative IVD Testing Solutions for Today and Tomorrow at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021

Fujirebio Diagnostics AB (Gothenburg, Sweden) highlighted its innovative IVD testing solutions at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany. More...

Fujirebio’s IVD product lines span from specialized manual testing to fully automated routine clinical laboratory testing solutions and include both novel and routine biomarkers. The company covers a variety of disease states such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism. At MEDICA 2021, Fujirebio presented LUMIPULSE G1200, a robust mid-sized fully automated immunoassay instrument that uses a unique mono test cartridge concept with a true throughput of 120 tests per hour. Also on display was the LUMIPULSE G600II, the latest member of the LUMIPULSE G series, the chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio. LUMIPULSE G600II is a compact and robust benchtop analyzer featuring a constant throughput of 60 tests per hour. The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories.

Among its kits for fully automated testing, Fujirebio highlighted Lumipulse® G B•R•A•H•M•S PCT, the most sensitive fully automated Procalcitonin (PCT) test. Immunoreaction cartridges for in vitro diagnostic (IVD) use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma. The CE marked assay utilizes proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes. Fujirebio showcased its portfolio of COVID-19 diagnostic tests, including the Lumipulse G SARS-CoV-2 S-IgG which is an assay system, including a set of immunoassay reagents, for the quantitative measurement of IgG-type antibodies SARS-CoV-2 spike protein (SARS-CoV-2 S-IgG) in specimens based on CLEIA technology by a specific two-step immunoassay method on the LUMIPULSE G System and with results that are available in up to 30 minutes.

In addition, Fujirebio highlighted the Lumipulse G SARS-CoV-2 Ag for in vitro diagnostic (IVD) use with the Lumipulse G system for the detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. The CE marked assay utilizes proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes.

Related Links:
Fujirebio Europe 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.